Table 3.

Serious adverse events. Serious Adverse Events (SAEs) presented per cohort CQ. The adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.03)

Dose level [mg]	SAE	CTCAE grade	Related to CQ	Action taken
200	Confusion	III	Unrelated	No adjuvant temozolomide
	Seizure	I	Unrelated	Increase dose anticonvulsants
	Fall (Trauma capitis)	II	Possibly	No action
	Thromboembolic event	IV	Unlikely	Anticoagulants
	Thromboembolic event	V	Unlikely	None
	Diarrhea	III	Possibly	i.v. fluids
	Nausea	III	Possibly	Stop chloroquine
	Vomiting	III	Possibly	Stop chloroquine
300	Nausea	III	Possibly	Stop chloroquine Stop temozolomide Stop radiotherapy
400	Hypercalcemia	II	Unlikely	i.v. fluids/bisphosphonates
	Blurred vision	III	Probably	Stop chloroquine
	Hallucinations	IV	Unrelated	Haloperidol

Serious Adverse Events (SAEs) presented per cohort CQ. The adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.03).